Ocugen (OCGN) Common Equity (2014 - 2026)
Ocugen's (OCGN) quarterly Common Equity came in at $5.8 million in Q1 2026, down 63.52% YoY from $15.9 million in Q1 2025, and up 147.71% on a QoQ basis from -$12.2 million in Q4 2025.
Ocugen (OCGN) Common Equity (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Common Equity data on file, last reported at $5.8 million in Q1 2026.
- Quarterly Common Equity fell 63.52% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 63.52% YoY) and the FY2025 annual result came in at -$12.2 million, down 141.06% from the prior year.
- Common Equity improved to $5.8 million in Q1 2026, from -$12.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $125.5 million in Q1 2022 to a low of -$12.2 million in Q4 2025.
- A 5-year average of $43.5 million and a median of $40.6 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 169.99% — and 2025, when it plunged 141.06%.
- Tracing OCGN's Common Equity over 5 years: stood at $74.0 million in 2022, then plunged by 45.17% to $40.6 million in 2023, then declined by 26.95% to $29.6 million in 2024, then sank by 141.06% to -$12.2 million in 2025, then surged by 147.71% to $5.8 million in 2026.
- The last three Common Equity figures came in at $5.8 million (Q1 2026), -$12.2 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -16.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.56 Mn |
| Mar 31, 2026 | 5.81 Mn |
| Dec 31, 2025 | -12.17 Mn |
| Sep 30, 2025 | 3.53 Mn |
| Jun 30, 2025 | 3.05 Mn |
| Mar 31, 2025 | 15.91 Mn |
| Dec 31, 2024 | 29.63 Mn |
| Sep 30, 2024 | 40.63 Mn |
| Jun 30, 2024 | 16.93 Mn |
| Mar 31, 2024 | 30.26 Mn |
| Dec 31, 2023 | 40.56 Mn |
| Sep 30, 2023 | 49.80 Mn |
| Jun 30, 2023 | 59.24 Mn |
| Mar 31, 2023 | 64.90 Mn |
| Dec 31, 2022 | 73.98 Mn |
| Sep 30, 2022 | 85.69 Mn |
| Jun 30, 2022 | 106.48 Mn |
| Mar 31, 2022 | 125.52 Mn |
| Dec 31, 2021 | 91.20 Mn |
| Sep 30, 2021 | 107.11 Mn |